Istari Oncology Initiates Its Phase I/II Sub-Study Evaluating PVSRIPO in Patients with Head and Neck Cancer
DURHAM, NC – August 17, 2021 – Istari Oncology, Inc., a clinical-stage biotechnology company focused…
DURHAM, NC – September 7, 2021 – Istari Oncology, Inc., a clinical-stage biotechnology company focused on novel immunotherapies for the treatment of solid tumors, today announced the company will participate in the following two virtual investment conferences taking place in September 2021:
Event: Morgan Stanley’s 19th Annual Global Healthcare Conference
Speaker: Executive leadership, Istari Oncology
Session Date/Time: Tuesday, September 14, 2021, from 5:00 – 5:30 p.m. EDT
Format: Fireside chat
Registration: Interested parties can attend the live webcast of Istari’s fireside chat here. The webcast will also be archived on www.istarioncology.com.
Event: H.C. Wainwright 23rd Annual Global Investment Conference
Speaker: Garrett Nichols, CMO, Istari Oncology
Session Date/Time: Available on-demand from September 13-15, 2021, beginning at 7:00 a.m. EDT
Format: Company presentation
Registration: Institutional investors can register for the conference and view Istari’s on-demand presentation here.
About Istari Oncology
Istari Oncology, Inc., headquartered in Research Triangle Park, North Carolina, is a privately held clinical-stage biotechnology company focused on novel immunotherapies for the treatment of glioblastoma and a wide variety of solid tumors. Istari has licensed a broad range of patents and patent applications and has access to additional intellectual property to continue clinical and commercial development of these technologies. The company’s primary asset currently in clinical development is PVSRIPO. For more information, please visit: www.istarioncology.com.
Stern Investor Relations